PT. RICHMOND, Calif., Feb. 19 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the Susquehanna Financial Group’s Second Annual SIGnificant Investment Options in Healthcare Conference at the W Hotel, 541 Lexington Avenue, in New York City on Tuesday, March 4, 2008 at 8:30 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company’s website at: http://www.transcept.com.
mgill@transcept.com scarrington@theruthgroup.comjrando@theruthgroup.com
CONTACT: Michael Gill, Director of Communications of Transcept
Pharmaceuticals, Inc., +1-510-215-3575, mgill@transcept.com; or investors,
Stephanie Carrington, +1-646-536-7017, scarrington@theruthgroup.com, or
media, Jason Rando, +1-646-536-7025, jrando@theruthgroup.com, both of The
Ruth Group, for Transcept Pharmaceuticals, Inc.
Web site: http://www.transcept.com/
http://www.transoral.com/
